The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical Experience with A Novel Large Bore Vascular Closure Device After Transfemoral TAVR

DOI: 10.4244/EIJ-D-19-00523

1. INSURE (Institute for Translational Cardiac Surgery), Department of Cardiovascular Surgery, German Heart Center, TUM, Munich, Germany; German Heart Center Munich, Department of Cardiovascular Surgery, TUM, Munich, Germany, Germany
2. INSURE (Institute for Translational Cardiac Surgery),Department of Cardiovascular Surgery,German Heart Center,TUM, Munich,Germany; German Heart Center Munich,Department of Cardiovascular Surgery,TUM,Munich,Germany
3. German Heart Center Munich,Department of Anaesthesiology,German Heart Center,TUM,Munich,Germany
4. Clinic for Thoracic and Cardiovascular Surgery,Heart and Diabetes Center NRW,Bad Oeynhausen,Germany
5. INSURE (Institute for Translational Cardiac Surgery),Department of Cardiovascular Surgery,German Heart Center,TUM, Munich,Germany; German Heart Center Munich,Department of Cardiovascular Surgery,TUM,Munich,Germany
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.

To read the full content of this article, please log in to download the PDF.

Utilization of TAVR is increasing. Vascular complications after transfemoral TAVR are still of concern. The majority is related to the large bore puncture site[1]. Currently, large bore arteriotomy closure relies on suture-based techniques, such as the Perclose Proglide® or Prostar XL® devices(Abbott, Redwood City, USA). Closure devices such as MANTA®(Teleflex, Morrisville, North Carolina) or PerQSeal®(Vivasure Medical, Galway, Ireland) designed to seal large bore arteriotomies became recently available. The novel InClosure®-VCD(InSeal Medical, Caesarea, Israel) provides hemostasis using a flexible intravascular biodegradable membrane supported by a nitinol frame (Figure 1). We report our single-center experience using the novel VCD.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Antithrombotic therapy after TAVI: where are we going?